II期临床试验-话题@MedSci

#II期临床试验#

174篇内容 | 3276人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931519, encodeId=0c8d193151988, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, objectType=article, longId=197670, objectId=9e0019e6706c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0019e6706c, replyNumber=0, likeNumber=85, createdTime=2021-03-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0019e6706c, moduleTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0019e6706c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931501, encodeId=93bb19315011f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=82, createdTime=2020-04-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931512, encodeId=53cd193151265, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=张伯礼：加快新冠病毒疫苗III期临床试验, objectType=article, longId=194542, objectId=0f3a194542ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3a194542ed, replyNumber=0, likeNumber=91, createdTime=2020-06-21, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3a194542ed, moduleTitle=张伯礼：加快新冠病毒疫苗III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3a194542ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931540, encodeId=a7ad1931540a9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, objectType=article, longId=203254, objectId=0697203254d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0697203254d7, replyNumber=0, likeNumber=82, createdTime=2020-12-29, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0697203254d7, moduleTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0697203254d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931490, encodeId=23fa19314906e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, objectType=article, longId=185521, objectId=11cc18552145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cc18552145, replyNumber=0, likeNumber=59, createdTime=2020-10-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cc18552145, moduleTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cc18552145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, objectType=article, longId=194690, objectId=fbb4194690aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbb4194690aa, replyNumber=0, likeNumber=62, createdTime=2021-01-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbb4194690aa, moduleTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbb4194690aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931508, encodeId=fad61931508aa, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, objectType=article, longId=193386, objectId=63df19338615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df19338615, replyNumber=0, likeNumber=61, createdTime=2021-02-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df19338615, moduleTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df19338615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931526, encodeId=ab0319315264b, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=50, createdTime=2021-03-02, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931502, encodeId=4b0e1931502c0, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=191296, objectId=4009191296a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4009191296a0, replyNumber=0, likeNumber=60, createdTime=2020-10-25, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4009191296a0, moduleTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4009191296a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931499, encodeId=cd98193149950, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, objectType=article, longId=189616, objectId=bc9018961683, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc9018961683, replyNumber=0, likeNumber=79, createdTime=2020-08-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc9018961683, moduleTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc9018961683)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931529, encodeId=a1c71931529ec, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, objectType=article, longId=201486, objectId=14fc201486bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fc201486bd, replyNumber=0, likeNumber=74, createdTime=2021-06-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fc201486bd, moduleTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fc201486bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931524, encodeId=8de2193152400, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, objectType=article, longId=199865, objectId=756f199865ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f199865ac, replyNumber=0, likeNumber=63, createdTime=2021-07-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f199865ac, moduleTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f199865ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931500, encodeId=d3b2193150074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, objectType=article, longId=190693, objectId=7c61190693ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c61190693ac, replyNumber=0, likeNumber=70, createdTime=2021-01-29, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c61190693ac, moduleTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c61190693ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931522, encodeId=428519315228d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, objectType=article, longId=198327, objectId=861219832eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861219832eff, replyNumber=0, likeNumber=51, createdTime=2021-04-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861219832eff, moduleTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861219832eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, objectType=article, longId=180576, objectId=5f001805e6d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f001805e6d8, replyNumber=0, likeNumber=82, createdTime=2020-03-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f001805e6d8, moduleTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f001805e6d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931489, encodeId=d9e719314894f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=58, createdTime=2020-03-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931498, encodeId=2b3d19314987f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=60, createdTime=2020-10-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931511, encodeId=8561193151176, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=0, createdTime=2020-06-25, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931495, encodeId=ce86193149556, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, objectType=article, longId=187677, objectId=e89218e67760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e89218e67760, replyNumber=0, likeNumber=71, createdTime=2020-06-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e89218e67760, moduleTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e89218e67760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931516, encodeId=92f71931516c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, objectType=article, longId=196221, objectId=32501962219e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32501962219e, replyNumber=0, likeNumber=71, createdTime=2021-04-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32501962219e, moduleTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32501962219e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床试验

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验

2021-03-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2020-04-22

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

张伯礼：加快新冠病毒疫苗III期临床试验

2020-06-21

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

JAHA：二甲双胍治疗肺动脉高压的II期临床试验

2020-12-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验

2020-10-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验

2021-01-10

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验

2021-02-12

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2021-03-02

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始

2020-10-25

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND

2020-08-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？

2021-06-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验

2021-07-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

2021-01-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行

2021-04-14

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

2020-03-15

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-03-12

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-10-30

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-06-25

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-06-10

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验

2021-04-04

科室
- - 订阅+
  - 更多科室
工具
服务